Dewpoint Therapeutics kicks off with $60m financing
Dewpoint Therapeutics has attracted interested of investors with a completely new approach that might cure a huge array of devasting diseases.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1118 entries already.
Entries by Thomas Gabrielczyk
IPO: Marinomed sets offer price
/in News/by Thomas GabrielczykMarinomed has set the offer price for its IPO at Vienna Stock Exchange at the lower limit of 75 per new share.
Novozymes partners with Carbios subsidiary Carbiolice
/in News/by Thomas GabrielczykNovozymes has entered into a partnership with French Carbios and its subsidiary Carbiolice, which aim to launch degradable bioplastics with limited lifespan for the packaging industry by 2020.
Biomarker predicts response to TNF blockers
/in News/by Thomas GabrielczykA new assay that accurately measures how arthritis patients respond to treatment with TNFalpha blockers such as adalimumab, open up the way to predict efficacy.
UK launches new payment model for antimicrobials
/in News/by Thomas GabrielczykIn order to incentivise drug companies to re-enter development of antibiotics, the UK government announced it will establish a licence model to assure developers sufficient return on investments (ROI).
BioNtech swallows MAB Discovery antibody unit
/in News/by Thomas GabrielczykImmunoncology and vaccine specialist BioNTech AG is broadening its antibody discovery capabilities by acquiring MAB Discoverys antibody generation unit.
Clariant inks cellulosic biodiesel pact with ExxonMobil/REG
/in News/by Thomas GabrielczykSwiss fine chemicals specialist Clariant has hammered out a R&D pact with ExxonMobil and Renewable Energy Group (REG) Inc to combine technologies in order of producing biodiesel from cellulose
IMI launches 80m call
/in News/by Thomas GabrielczykThe Innovative Medicines Initiative II has earmarked 80m for pre-competetive research improving the pharmaceutical industry’s productivity.
AMR: Novo Holdings funds companies with 18m
/in News/by Thomas GabrielczykNovo Holdings has invested 18m from its 135m REPAIR Impact Fund into four companies.
Boehringer expands neurology activities
/in News/by Thomas GabrielczykBoehringer Ingelheim has expanded its 2014 R&D collaboration with the BioMed X Innovation Center (Heidelberg, Germany) to find new treatment approaches for early intervention of psychiatric diseases.